Showing 4921-4930 of 10632 results for "".
- Aditxt to Initiate First In-Human Clinical Trials with its Therapeutics Programs in Psoriasishttps://practicaldermatology.com/news/aditxt-to-initiate-first-in-human-clinical-trials-with-its-therapeutics-programs-in-psoriasis/2460724/Aditx Therapeutics, Inc.’s AditxtReprogramming Therapeutics Division is preparing its to begin first-in-human clinical
- AbbVie Presents Additional Phase 3 Data for Upadacitinibhttps://practicaldermatology.com/news/abbvie-presents-additional-phase-3-data-on-upadacitinib/2460591/Significantly more patients treated with AbbVie’s upadacitinib in both of the Measure Up 1 and 2 studies
- BTL HIFEM Devices Honored by Harper's Bazaar, NewBeautyhttps://practicaldermatology.com/news/btl-hifem-devices-honored-by-harpers-bazaar-newbeauty/2459976/BTL has received two new accolades from NewBeauty and Harper's Bazaar
- The Complexion of Climate in Medical Educationhttps://practicaldermatology.com/news/the-complexion-of-climate-in-medical-education/2461992/The morning news warned us of a heatwave, but that didn’t stop 8-year-old me from putting on my usual red hoodie. The avoidance of prying eyes or hearing “is it contagious?” another time made the sweating worth it. Atopic dermatitis (AD) had claimed my skin as its home, marking
- Cutera, Inc. Appoints Jeff Jones as COOhttps://practicaldermatology.com/news/cutera-inc-appoints-jeff-jones-as-coo/2461956/Jeff Jones is Cutera, Inc.’s new Chief Operating Officer, effective August 28, 2023. Mr. Jones will report directly to Taylor Harris, Cutera’s Chief Executive Officer, and will be responsible for end-to-end operations, including manufacturing, quality, supply chain, fi
- FDA Approves Verrica Pharmaceuticals’ YCANTH for Molluscum Contagiosumhttps://practicaldermatology.com/news/fda-approves-verrica-pharmaceuticals-ycanth-for-molluscum-contagiosum/2461882/The U.S. Food and Drug Administration (FDA) has given its nod to Verrica Pharmaceuticals Inc.’s YCANTH (cantharidin) topical solution for the treatment of molluscum contagiosum in adult and pediatric patients aged two and older. "It's the only topical FDA-approved therapy
- Venus Concept Announces Medical Advisory Board for AI.ME, Its Next Generation Robotic Platformhttps://practicaldermatology.com/news/venus-concept-announces-medical-advisory-board-for-aime-its-next-generation-robotic-platform/2461872/Meet Venus Concept Inc.’s medical advisory board for AI.ME, its next generation robotic platform. The primary mission of the medical advisory board will be to provide strategic input, guidance, and clinical recommendations regarding the Company's emerging robotic technolo
- Biosimilar Update: FDA Accepts Dr. Reddy’s Proposed Rituximab Biosimilar Application for Reviewhttps://practicaldermatology.com/news/biosimilar-update-fda-accepts-dr-reddys-proposed-rituximab-biosimilar-application-for-review/2461859/Dr. Reddy’s Laboratories Ltd’s Biologics License Application (BLA) for its proposed biosimilar rituximab candidate DRL_RI has been accepted for a substantive review by the U.S. Food and Drug Administration (FDA). This closely follows acceptance of its rituximab biosimi
- Dove, Gracie's Corner Join Forces to Educate Families on the CROWN Movementhttps://practicaldermatology.com/news/dove-gracies-corner-join-forces-to-educate-families-on-the-crown-movement/2461777/Dove is joining forces with "Gracie's Corner," a children's YouTube series, to celebrate the beauty of natural hair and help educate families about the need to Create a Respectful and Open Wo
- Incyte Taps Dr. Pablo J. Cagnoni for New Leadership Rolehttps://practicaldermatology.com/news/incyte-taps-dr-pablo-j-cagnoni-for-new-leadership-role/2461704/Pablo J. Cagnoni, MD, is Incyte’s New President and Head of Research & Development, effective June 5, 2023. In this role and as a member of the Executive Team, Dr. Cagnoni will lead Incyte’s R&D efforts across its portfolio of programs in oncology, hematol